STOCK TITAN
  1. Home
  2. News
  3. IMAB

I-Mab - IMAB STOCK NEWS

Welcome to our dedicated news page for I-Mab (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-Mab.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect I-Mab's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of I-Mab's position in the market.

News
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
I-Mab (IMAB) to present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024, focusing on immunotherapies for cancer treatment. The presentation will feature key executives and offer opportunities for one-on-one meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
conferences
-
News
I-Mab Announces Closing of the Divestiture of Business Operations in China
Rhea-AI Summary
I-Mab successfully closes divestiture transaction transferring equity interest in I-Mab Shanghai, with a total consideration of up to US$80 million. The Company extinguishes repurchase obligations of approximately US$183 million and participates in Series C fundraising of the Hangzhou Company for US$19 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
-
News
I-Mab Reports Full Year 2023 Financial Results and Business Update
Rhea-AI Summary
I-Mab reports positive clinical results for uliledlimab and givastomig, plans strategic divestiture in China, and discloses financial results for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
earnings
News
I-Mab Signs Agreement to Divest its Assets and Business Operations in China
Rhea-AI Summary
I-Mab (IMAB) has entered into definitive agreements to divest its assets and business operations in China, marking a strategic shift to become a U.S.-based biotech. The agreement provides for a focus on advancing oncology clinical assets, reducing operational costs, and retaining cash in hand, while streamlining the operating model. The company retains ex-China rights to clinical stage assets and aims to remain listed on NASDAQ. The Hangzhou Company will acquire I-Mab drug assets in China, and the Company will participate in the Series C fundraising of the Hangzhou Company for an equity interest subscription of US$19 million in cash. Management and personnel changes include the appointment of an Interim Chairperson and a new Chief Financial Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
-
News
I-Mab Announces Participation at Jefferies and Piper Conferences in November
Rhea-AI Summary
I-Mab, a global biotechnology company, will be participating in two conferences in November 2023: the Jefferies London Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference. The company's CEO, Dr. Raj Kannan, and CMO, Dr. John Hayslip, will be presenting at both conferences. The conferences will provide opportunities for one-on-one and small group meetings with management. The webcast of the Jefferies conference will be available on I-Mab's IR website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
none
-
News
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)
Rhea-AI Summary
The FDA has granted Breakthrough Therapy Designation for felzartamab, an investigational CD38 antibody, for the treatment of primary membranous nephropathy (PMN). I-Mab and HI-Bio announced that felzartamab has shown promising data, and the Phase 3 multiple myeloma data is expected in 2024. I-Mab has full development and commercialization rights for felzartamab in Greater China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.15%
Tags
none
News
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
Rhea-AI Summary
I-Mab (Nasdaq: IMAB) announced that two poster presentations featuring preclinical data on givastomig and TJ-L14B/ABL503 will be reported at the 38th Society for Immunotherapy of Cancer's Annual Meeting. The presentations will focus on the tumor-killing and anti-tumor activity of these bispecific antibody assets in the treatment of gastric cancer and the reinvigoration of exhausted tumor-infiltrating CD8+ T cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.99%
Tags
none
-
News
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
Rhea-AI Summary
I-Mab to present updated clinical results of givastomig in advanced solid tumors at ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
clinical trial
-
News
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
Rhea-AI Summary
I-Mab announces recent developments in TJ-L14B/ABL503, a differentiated PD-L1 x 4-1BB bispecific antibody. Patent rights secured until 2039. Phase 1 study shows promising preliminary efficacy signals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.38%
Tags
none
News
I-Mab Announces Upcoming Participation at September Conferences
Rhea-AI Summary
I-Mab announces its participation in two upcoming conferences in September 2023, where management will give presentations and hold meetings. The conferences are the H.C. Wainwright 25th Annual Global Investment Conference and the 2023 Cantor Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.73%
Tags
none
Stock IMAB logo
I-Mab

Nasdaq:IMAB

IMAB Rankings

#3994 Ranked by Market Cap
#5074 Ranked by Stock Gains
N/A Ranked by Dividends

IMAB Stock Data

146.07M
122.60M
1.06%
35.07%
1.45%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
China
Shanghai

About IMAB

i-mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. it is developing felzartamab (tj202), a cd38 antibody that is in phase iii clinical trials to treat multiple myeloma and autoimmune diseases; eftansomatropin (tj101), a long-acting human growth hormone that has completed phase ii clinical trials to treat pediatric growth hormone deficiency; and olamkicept (tj301), a il-6 blocker, which is in phase ii clinical trials for the treatment of ulcerative colitis and autoimmune diseases. the company's product candidates also include enoblituzumab, a humanized b7-h3 antibody that has completed phase i clinical trials to treat head and neck cancer and other oncology diseases; efineptakin (tj107), a long-acting recombinant human il-7, which is in phase 2 clinical trials to treat glioblastoma multiforme (gbm